Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;94(8):E209-E213.
doi: 10.1002/ajh.25505. Epub 2019 May 21.

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy

Victor A Chow  1   2   3 , Ajay K Gopal  1   2   3 , David G Maloney  1   2   3 , Cameron J Turtle  1   2   3 , Stephen D Smith  1   2   3 , Chaitra S Ujjani  1   2   3 , Mazyar Shadman  1   2   3 , Ryan D Cassaday  1   2   4 , Brian G Till  1   2   3 , Yolanda D Tseng  2   5 , Edus H Warren  1   2   3 , Andrei R Shustov  1   2   4 , Manoj P Menon  1   4 , Sandra Bhark  2   6 , Utkarsh H Acharya  1   2   3   7 , Erin Mullane  2 , Lindsay M Hannan  1   2   3 , Jenna M Voutsinas  8 , Ted A Gooley  1   8 , Ryan C Lynch  1   2   3
Affiliations

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy

Victor A Chow et al. Am J Hematol. 2019 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTERESTS

Figures

FIGURE 1
FIGURE 1
OS results analyzed using Kaplan-Meier methodology and are shown for the overall population A, and by timing of progression (B, Early PD vs Late PD). OS, overall survival; PD, progressive disease
See this image and copyright information in PMC

References

    1. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. - PMC - PubMed
    1. Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52:216–221. - PubMed
    1. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Onc. 2010;28:4184–4190. - PMC - PubMed
    1. Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood. 2018;132(8):777–781. - PMC - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377:2531–2544. - PMC - PubMed

Publication types